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Available online 2 May 2008The E6 oncoproteins of the cancer-associated human papillomaviruses (high-risk HPV types) characteristically
have a PDZ-binding motif at their extreme carboxy-termini. However, they interact with only some of the PDZ
domain-containing proteins in the human proteome and, despite many of these proteins having multiple PDZ
domains, they interact speciﬁcally through only one of those domains. Previouswork has shown that the exact
sequence of the C-terminal PDZ-binding motif of E6 affects substrate selection, and recently we have shown
that an E6 residue peripheral to the binding motif also contributes to the speciﬁcity of binding.
Here we show that substrate speciﬁcity of the HPV E6 PDZ binding is modulated both by the amino acid
residues upstream of the binding domain and by the non-canonical residues within it. Using this datawe have
begun to construct a scheme of substrate preferences for E6 proteins from different HPV types.







The E6 proteins of the high-risk HPV types (such as HPV-16 and
HPV-18) interact with a large number of cellular proteins. Some of
these proteins, such as p53 and Bak (Storey et al., 1998; Thomas and
Banks, 1999) are also targeted by the E6 proteins from low-risk virus
types, and by E6 from cutaneous HPV types (Jackson et al., 2000). The
PDZ domain-containing proteins, however, are targeted exclusively by
the high-risk mucosotropic viruses. These targets include the Dlg and
hScrib tumour suppressors; MAGI-1, -2 and -3; MUPP1 and PATJ,
amongst others (Gardiol et al., 1999; Glaunsinger et al., 2000; Latorre
et al., 2005; Lee et al., 2000; Nakagawa and Huibregtse, 2000; Thomas
et al., 2002). Several of these proteins are implicated in the control of
cell growth and polarity (Bilder et al., 2000), and viral interactionwith
these proteins in the differentiating epithelium is presumably re-
quired to maintain the epithelial cells in a state that is suitable for viral
replication.
High-risk HPV E6 proteins have type 1 PDZ-binding motifs at their
extreme C-termini (ETQL in HPV-16 E6; ETQV in HPV-18 E6), and we
have previously used end-swap mutations to show that the identity of
the ﬁnal amino acid has a profound effect upon the ability of the
protein to bind different targets (Thomas et al., 2001). Most strikingly,
the higher afﬁnity of HPV-16 E6 for hScrib and of HPV-18 E6 for Dlg
can be completely reversed by swapping only the last amino acid
residue of E6 (Thomas et al., 2005). In addition, it has become clearl rights reserved.from several studies that, although many PDZ-containing targets have
multiple PDZ domains, generally only one of them is bound with high
speciﬁcity by E6 (examples being the Dlg PDZ2, the MUPP1 PDZ10 and
the PDZ1 domain of the MAGI-1, -2 and -3 proteins) (Gardiol et al.,
1999; Lee et al., 2000; Thomas et al., 2001, 2002, 2005).
Studies using crystal structure analysis have provided models that
clarify the physical constraints that underlie both the folding of the
PDZ domains themselves and the interactions of the domains with
their preferred ligands (Doyle et al., 1996; Grembecka et al., 2006;
Wilken et al., 2004). A recent study (Zhang et al., 2007) has also shown
the importance of amino acid residues outside the consensus binding
motif in contributing to the strength of a PDZ domain-ligand inter-
action. This study demonstrated that the Arginine residue immedi-
ately upstream of the PDZ-binding motif also contributes to the
binding of HPV-18 E6 to MAGI-1 and to Dlg. Furthermore, mutation of
this residue results in a greatly reduced ability to bind to Dlg or MAGI-
1 and to induce their degradation (Zhang et al., 2007). Interestingly,
although they could obtain the co-crystallisation of an E6 peptidewith
a PDZ domain with which it does not interact in vivo, the data showed
clearly that other residues were required to give speciﬁcity to the
interaction; thus conﬁrming the importance of upstream sequences.
Since the carboxy-terminal sequences of high-risk HPV E6
proteins are highly conserved even outside the core PDZ-binding
motif it seemed possible that the similarities, and differences, in the
sequences might also inﬂuence the interaction with speciﬁc PDZ
domains: potentially directing the speciﬁcity of binding. To address
this question, we have generated a series of HPV-18 E6 mutants
with lesions in the conserved residues upstream of the PDZ-binding
Fig. 1. Protein sequences of the C-terminal portion of HPV-18 E6 wild type plus the
mutants used in this study. Mutations are shown in red (or green in the case of the 156
mutant).
372 M. Thomas et al. / Virology 376 (2008) 371–378motif and used them to analyse the contribution of these residues
to speciﬁcity of interaction. Our results show that residues upstream
of the core PDZ-binding motif are indeed involved in binding, andTable 1
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l.that mutation of these residues can affect the ability of E6 to bind
or induce the degradation of various PDZ domain-containing tar-
gets. This implies that considerable discriminatory effects are
mediated by regions of the protein outside the canonical binding
motif and suggests the possibility of speciﬁc therapeutic inter-
ference with certain interactions, both in HPV disease and in other
malignancies.
Results
Our previouswork (Zhang et al., 2007) had shown that a C-terminal
peptide of HPV-18 E6 (−7RRRETQV−1, where −1 is the ﬁnal amino acid
of the protein) could bind, via the consensus—XTXVPDZmotif, to both
PDZ2 and PDZ3 of the Dlg protein. This crystallisation study showed
that the −5 residue (R154) of the peptide also bound to the Dlg PDZ2
but not to the PDZ3 domain and was thus instrumental in selecting
PDZ2 as the speciﬁc target of HPV-18 E6, providing a biophysical
explanation for a previously observed biological phenomenon.
Similarly, this residue binds strongly to the MAGI-1 PDZ1, also
previously deﬁned as the E6-speciﬁc target (Glaunsinger et al., 2000;
Thomas et al., 2002). The overall arrangement of all HPV E6 proteins is
generally well conserved, but the C-terminal tail of the oncogenic
mucosotropic types is very highly conserved; we were therefore
interested in knowing whether any of these conserved residues were
also able to contribute to binding speciﬁcity. Accordingly, we
constructed a series of mutants in which each of the highly conserved
residues was mutated either to an Alanine or Glycine, and these are
shown in Fig. 1.nalysed by phosphorimager and the results show the collated results of at least 3 assays
hich is standardised to 100%. These results are represented as histograms in the lower
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Having obtained speciﬁc point-mutated HPV-18 E6 proteins we
proceeded to analyse their activities in in vitro degradation assays. The
E6 proteins were translated in vitro and incubated for the times
indicated with in vitro translated Dlg, MAGI-1 and MAGI-3 proteins,
each of which has been shown previously to be detectably targeted by
E6 in these assays (Gardiol et al., 1999; Thomas et al., 2001, 2002).
Since previous studies had demonstrated that deletion of the entire
carboxy-terminal tail of HPV-18 E6 ablated its ability to induce the
degradation of p53 (Pim et al., 1994), but that the PDZ-binding motif
plays no role in p53 binding, we also included p53 in these analyses.
These and subsequent assays were analysed by SDS-PAGE and
autoradiography. They were then analysed by phosphorimager and
the collated results of at least three assays per E6 mutant are
summarised in Table 1.
We started by looking at the effects of mutating the conserved
residues that arewell upstream of the PDZ-bindingmotif. It can be seen
from Fig. 2 that wild type HPV-18 E6 efﬁciently targets all of these
proteins for degradation in vitro; it can also be seen that neither the
R146A nor Q147A mutants is as efﬁcient as wild type in inducing the
degradation of p53. Interestingly, the R146A mutant, although less
efﬁcient than the Q147A mutant at inducing p53 degradation, is more
efﬁcient at inducing the degradation of the PDZ domain-containing
targets, suggesting that thismay deﬁne a boundary between the regions
of E6 involved in p53 interaction and those involved in PDZ interactions.
The contribution of upstream Arginine residues to E6/PDZ interactions
Previous work has shown the importance of the HPV-18 E6
Arginine 154 residue in mediating the binding and degradation of Dlg
and of MAGI-1 (Zhang et al., 2007). Mutation of this residue to Glycine
results in a severe reduction of E6's ability to bind to, or induce the
degradation of, Dlg or MAGI-1. Since there are a number of highly
conserved Arginine residues in this regionwewere interested in their
potential contribution to binding speciﬁcity. We therefore incorpo-
rated the Q151A, R152G and R153G mutants into the in vitro de-
gradation assays and the results are shown in Fig. 3. It is clear thatFig. 2. In vitro degradation assay using p53, Dlg, MAGI-1 and MAGI-3 as targets:
comparison of the activities of thewild type HPV-18 E6withmutants R146A and Q147A.
Samples were taken at the time-points indicated and the E6 inputs are shown in the
lower panel.neither 151A nor 152G has any signiﬁcant effect on the degradation of
these targets. However, it can be seen that the 153G mutant is less
effective than wild type at inducing the degradation of MAGI-1,
indicating that this residue may contribute to the binding of E6 to
MAGI-1, but not to the binding of MAGI-3 or of Dlg.
The effects of mutating canonical and non-canonical residues of the PDZ-
binding motif
Since the canonical type I PDZ-binding motif, XT/SXV, appears to
allow a certain amount of variation within it (X signifying any amino
acid), wewere interested to know towhat extent those residuesmight
contribute to E6's interaction with its targets. We therefore assayed
the in vitro degradation activity of the E155A, T156S and Q157A
mutants; the results are shown in Fig. 4A, together with those using
the R154G mutant, for comparison. The V158A mutation was not
included in these assays, as it has been demonstrated many times to
abolish binding completely (Gardiol et al., 1999; Glaunsinger et al.,
2000; Thomas et al., 2001).
In Fig. 4A it can be seen that the very highly conserved E155 is
absolutely required for the degradation of Dlg, indicating its impor-
tance for the E6–Dlg interaction. It also contributes to the E6–MAGI-3
interaction, but is not required for the interaction with MAGI-1. Also,
interestingly, the 154G mutation, so devastating to E6's interactions
with Dlg and MAGI-1, has little or no effect on the degradation of
MAGI-3, these data together suggest that E6 has a different mode
of interaction with the two MAGI proteins. These differences are
addressed in Fig. 5.
Clearly, the ability of E6 to bind a target protein, and its ability to
induce degradation of that protein are not necessarily the same,
although it is very likely that binding will correlate well with de-
gradation in the case of these highly deﬁned mutations. However, to
assess the binding of certain of the E6 mutants we performed GST
pull-down assays with the in vitro translated E6 mutants with either
GST alone or GST-Dlg. The results are shown in Fig. 4B, where it can be
seen that, as expected, the wt E6 binds strongly to GST-Dlg and the
R154G mutant is severely impaired in binding (Gardiol et al., 1999;
Zhang et al., 2007). Interestingly, the R153G mutant, which exhibits
wild type degradation activity, is unimpaired in its binding, and the
same is true of the Q157A mutant. However, the E155A and T156S
mutants, which are impaired in their ability to induce Dlg degradation,
are also markedly reduced in their ability to bind to GST-Dlg. Thus the
phenotypes of the mutants with respect to their activity in inducing
Dlg degradation is reﬂected in their ability to bind GST-Dlg.
The importance of Threonine
The type 1 PDZ-bindingmotif can, apparently, contain either a Serine
or a Threonine residue at position −3, although the majority of HPV E6
PDZ-binding motifs contain Threonine. We were interested to know
whether this was essential for interactionwith the E6 target proteins. In
Fig. 4A it can be seen that the presence of a Threonine residue at position
156 is essential for degradation of Dlg and ofMAGI-1, but that Serine can
be substituted without detriment to the degradation of MAGI-3. This
underlines the differences between the E6–MAGI-1 and E6–MAGI-3
interactions, which will be further discussed in reference to Fig. 5E
below. It also suggests that there may be a difference in target selection
in those HPV types that have a Serine residue in this position.
Modelling the differences and similarities between MAGI-1 and MAGI-3
PDZ1 domains
The results of our analyses suggest that MAGI-1 andMAGI-3 differ
substantially in their susceptibility to degradation by the various
HPV-18 E6 mutants. To investigate this further, the MAGI-3 PDZ1
domain was modelled, based on our crystal structures of the MAGI-1
Fig. 3. Invitrodegradationassay usingp53,Dlg,MAGI-1 andMAGI-3 as targets: comparison
of theactivities of thewild typeHPV-18E6withmutantsQ151A,R152GandR153G. Samples
were taken at the time-points indicated and the E6 inputs are shown in the lower panel.
374 M. Thomas et al. / Virology 376 (2008) 371–378PDZ1 domain (PDB code 2I04; Zhang et al., 2007). The results of this
modelling and the comparison with the crystal structures are shown
in Fig. 5.Fig. 4. A. In vitro degradation assay using p53, Dlg, MAGI-1 and MAGI-3 as targets: comparis
Q157A. Samples were taken at the time-points indicated and the E6 inputs are shown in the
incubated with in vitro translated wild type and mutant HPV-18 E6 proteins. The two uppe
protein bound above the relevant track. The two right-hand panels show the Coomassie Blu
proteins.In Fig. 3 we had seen that the R153Gmutant has no effect upon the
susceptibility of MAGI-3 to degradation, although the R153 residue
clearly contributes to MAGI-1 binding. In the crystal structure of
MAGI-1 PDZ1 bound to the HPV-18 E6 peptide, we see that the R153
residue of E6 sits directly above the MAGI-1 PDZ1 V467 residue and
bonds with the Q477 (coloured cyan in Fig. 5C), therefore the R153G
mutation would be expected to reduce the binding, leading to a
change in MAGI-1 degradation. However, the MAGI-3 PDZ1 has an
Isoleucine (I65) in place of the V467 of MAGI-1 PDZ1 (coloured pink in
Fig. 5C), which could hinder the interaction between R153 of E6 and
Q75 of MAGI-3 (equivalent toMAGI-1 Q477). Thus the E6 residue R153
would not contribute signiﬁcantly to binding MAGI-3 and the R153G
mutant would not cause any signiﬁcant change in the binding or
degradation of MAGI-3, as indeed we see in Fig. 3. Similarly, the other
possible rotameric conformations of I65 (not shown), might be
expected to perturb those water-mediated main-chain interactions
of E6 R154 with the PDZ βB–βC loop that were observed in the crystal
structures of E6 with MAGI-1 and Dlg. Thus the I65 of MAGI-3 may
also weaken the binding of E6's R154 with MAGI-3 PDZ1, providing a
molecular explanation for the observation in Fig. 4A that R154 has
little or no effect upon MAGI-3 degradation.
Fig. 4A also shows that the E155A mutant has little effect upon the
degradation of MAGI-1, whereas MAGI-3 degradation is reduced.
Modelling, shown in Fig. 5D, showswhy the interaction between HPV-
18 E6 E155 and MAGI-1 PDZ1 is not likely, whereas a hydrogen bond
between E155 and MAGI-3 PDZ1 is favoured. The MAGI-3 PDZ1
residue N78 can interact with E6 E155, while the MAGI-1 equivalent,
S480, could not interact with E155. Thus MAGI-3 PDZ1, but not MAGI-
1 PDZ1, interacts strongly with the HPV-18 E6 E155 and the E155Aon of the activities of the wild type HPV-18 E6 with mutants R154G, E155A, T156S and
lower panel. B. GST pull-down assays using bacterially expressed GST alone or GST-Dlg
r left-hand panels show autoradiographs of the E6 protein bound, with the % of input
e-stained SDS-PAGE gels, the lower left panel shows 20% of input in vitro translated E6
Fig. 6. GST pull-down assays using bacterially expressed GST alone, GST-Dlg or GST
fused to MAGI-1 PDZ domain 1 (M1P1) incubated with in vitro translated HPV E6
proteins. The histogram shows the percentage of input protein bound and represents
the collated results of three assays. Standard deviations are shown.
Fig. 5. Structural basis for differential speciﬁcity of HPV-18 E6 for PDZ1 from MAGI-1 and MAGI-3. A. Sequence alignment of the PDZ1 of MAGI-1 and MAGI-3. Despite their marked
sequence similarities, mutational analysis indicates that their binding afﬁnities for HPV-18 E6 differ substantially. B. Crystal structure of HPV-18 E6 peptide binding to MAGI-1 PDZ1
(PDB code: 2I04, Zhang et al., 2007). C. The modelled binding of HPV-18 E6 to MAGI-3 PDZ1 (pink), superimposed on the crystal structure of HPV-18 E6 binding to MAGI-1 PDZ1
(cyan). The interaction of R153 of HPV18 E6withMAGI-1 PDZ1may be perturbed by the change of V467 to Ile inMAGI-3, inwhich the extramethyl group of Ile sterically hinders R153
of E6. D. In the samemodel as in panel C, residue E155 of HPV-18 E6 is predicted to have stronger interactionwith MAGI-3 PDZ1 thanwith MAGI-1 PDZ1 and Dlg PDZ2 because of the
substitution of N79 in MAGI-3 for the Ser in MAGI-1 (S480) and Dlg. E. Probable interactions of HPV-18 E6 T156S mutant with MAGI-3 PDZ1 in the modelled complex structure.
F. Q157 of HPV-18 E6 can adopt different conformations, as seen in the crystal structures of the MAGI-1 PDZ1–E6 (E6 shown in yellow) and Dlg PDZ3–E6 complexes (E6 shown in
grey). MAGI-1 PDZ1 is shown in cyan (PDB codes: 2I04 and 2I01).
375M. Thomas et al. / Virology 376 (2008) 371–378mutation reduces MAGI-3 binding and degradation while having very
little effect on MAGI-1 degradation.
Although a conservative mutation from T156 to a Serine has no
effect upon MAGI-3 degradation, it is highly detrimental to the
degradation of MAGI-1 and Dlg. The reasons are addressed by our
crystal structures and by the models shown in Fig. 5E. The crystal
structures obtained previously (Zhang et al., 2007) showed that the
side chain of E6's V158 ﬁts well into the hydrophobic groove of the
MAGI-1 PDZ1 and the side chain of T156 forms a hydrogen bond with
a highly conserved Histidine residue (H512) in the PDZ domain. In
addition, the side-chain methyl group of T156 contributes to the
hydrophobicity of the groove, which is required for the V158 binding.
The model of MAGI-1 PDZ1 bound to the E6 T156S mutant (Fig. 5E)
shows that the S156 can hydrogen bond with the conserved Histidine
residue, but it lacks the important methyl group. In MAGI-3 PDZ1, a
methyl group can be provided by I64, tomaintain local hydrophobicity
and thus facilitate V158 binding. In contrast, MAGI-1 PDZ1 has a
Valine (V466) at the equivalent position, which, having no extra
methyl group, is unable to maintain sufﬁcient hydrophobicity with a
Serine-containing ligand and thus the binding is disrupted.
Fig. 4A also showed that while HPV-E6 Q157A mutation com-
pletely ablates E6's ability to induce MAGI-1 degradation, it has little
or no effect on MAGI-3 or Dlg degradation. The crystal structures of
HPV-18 E6 bound to PDZ domains (Zhang et al., 2007) showed that the
E6 Q157 can adopt different conformations, depending on the PDZ to
which E6 is bound (Fig. 5F). In the MAGI-1 PDZ1–E6 structure, Q157 of
E6 forms hydrogen bonds with the PDZ while in the Dlg PDZ3–E6
complex, Q157 faces the solvent and does not interact with the PDZ.Similarly, Q157 does not bind MAGI-3 PDZ1 and hence the Q157A
mutation cannot affect the E6/MAGI-3 PDZ interaction, in contrast to
its marked detrimental effect on E6/MAGI-1 PDZ1 interaction as
shown in Fig. 4A. This demonstrates that E6's Q157 can adopt various
conformations, and thus its interaction with PDZ domains is non-
uniform and appears to be speciﬁc to the individual PDZ domain.
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Having shown that the contributions of each amino acid residue of
the PDZ-binding domain differed, depending upon the PDZ domain
targeted, and that these differences were supported by the modelling
analysis, we wanted to know whether similar differences could be
seen in wild type E6 proteins derived from different HPV types. To do
this we performed GST pull-down assays using in vitro translated E6
proteins from several high-risk HPV types. These were incubated with
GST alone, with GST-Dlg and with GST-M1P1, which is the PDZ1
domain of MAGI-1, previously deﬁned as the HPV-18 E6 target domain
(Glaunsinger et al., 2000; Pim et al., 2002). The bound proteins were
analysed by SDS-PAGE and phosphorimager analysis and the collated
results of several assays are shown in Fig. 6. It can be seen that, as
expected, the HPV-18 E6 binds strongly to GST-Dlg and to GST-M1P1
and the highly homologous HPV-45 E6 also binds strongly to these
fusionproteins. Interestingly, the E6 proteins fromHPV-53 (TTATESAV)
and HPV-89 (AARRPSRI) both show reduced binding to GST-Dlg
and to GST-M1P1. Comparison with the mutational and modelling
analyses would tend to support this; thus the HPV-53 E6 TE - - V
residues could contribute to binding Dlg whereas the S would weaken
the Dlg binding, and the penultimate A residue would markedly
weaken the M1P1 binding. The HPV-89 E6 RR - - R - residues could all
contribute to the binding of Dlg, and while the presence of a Proline is
likely to increase the rigidity of the motif, thus limiting the substrate
range, the Isoleucine might compensate for the lower hydrophobicity
of the Serine residue in the binding groove. Thus the binding of E6
proteins from other high-risk HPV types to PDZ domain targets can be
analysed in the light of the predictions made from the mutational
analysis of HPV-18 E6.
Discussion
There are many PDZ domain-containing proteins in the human
proteome and a signiﬁcant proportion of them contain more than
three PDZ domains. However, the high-risk HPV E6 proteins bind to
only some of these proteins and, apparently, through only one of the
PDZ domains per protein. It is clear that there must be additional
factors in the E6 sequence or structure that can determine the
speciﬁcity of binding. It has also been shown that the PDZ target
selection can be inﬂuenced by all of the residues of the binding motif
(Stifﬂer et al., 2007). Using the data presented here, together with the
results of a crystallographic analysis (Zhang et al., 2007), we can begin
to dissect the speciﬁcity determinants of the HPV-18 E6 protein for its
various PDZ domain-containing targets.
We ﬁrst showed that the 146 and 147 mutants of HPV-18 E6 may
deﬁne a boundary between the region of E6 involved in p53
interaction and the region involved in PDZ interaction. It has been
shown by a number of mutational analyses that the p53-related region
of E6 comprises a large part of the molecule (Lagrange et al., 2005;
Nominé et al., 2006; Pim et al., 1994) and it may be surmised that it is
the integrity of the overall structure of E6 in this region that is
required for the E6/p53 interaction, including a part of the C-terminal
tail. The PDZ interaction domain (i.e. the canonical XTXV motif, plus
the modiﬁers described here) is more discrete, reﬂecting the deﬁned
nature of the C-terminal PDZ interaction.
The Arginine residues immediately upstream of the PDZ motif are
highly conserved amongst the high-risk mucosal HPV types and it
might have been predicted that they would play a role in the in-
teraction. Indeed, the Arginine 153 contributes to the binding to
MAGI-1 PDZ1 but, interestingly, not to the binding of Dlg nor to MAGI-
3 PDZ1. When correlated with our crystallographic data (Zhang et al.,
2007), the reasons for this become clear: R153 hydrogen bonds with
downstream residues of the MAGI-1 PDZ1, but is sterically blocked
from bonding with the equivalent residues of Dlg PDZ2 owing to the
longer βB–βC loop of this PDZ domain. Interestingly, the equivalentresidues in the Dlg PDZ3 domain (which was co-crystallised with E6
peptide by Zhang and colleagues, but which is not a target in vivo) are
hydrophobic and thus cannot form such hydrogen bonds with E6.
The importance of the R154 residue of E6 in contributing to the
interaction with both the MAGI-1 and Dlg proteins has been de-
monstrated previously (Zhang et al., 2007). Our crystallographic data
shows that the R154 hydrogen bonds with the βB–βC loop of MAGI-1
PDZ1 and makes a salt bridge across to the αB helix of Dlg PDZ2, but
that no side-chain interactions are seen with the non-target Dlg PDZ3
domain; this is shown more clearly in Fig. 7, adapted from Zhang et al.
(2007). Examination of the protein sequences of the high-riskmucosal
HPV E6 proteins (which can be seen in Fig. 8) emphasises the high
degree of conservation of this residue throughout this group of
viruses, and suggests that the PDZ domain interactions that are en-
hanced by the presence of this residue are likely to be of great im-
portance in the viral life cycle.
The E155 residue is also highly conserved through the high-risk
mucosal E6 proteins and it is interesting that mutating this residue to
Alanine disrupts the binding degradation of Dlg and MAGI-3 but has
little or no effect upon the degradation of MAGI-1. Crystal structures
show that the E155 side chain can hydrogen bond with MAGI-1 PDZ1,
Dlg PDZ2 and Dlg PDZ3. However, since the Dlg PDZ3 interaction does
not occur in vivo this suggests that E155 binding cannot confer
speciﬁcity on an interaction in the absence of other speciﬁc bonds. It
also suggests that in MAGI-1 PDZ1, which has a large number of
speciﬁc bondswith E6, the loss of theweak E155-mediated bond is not
sufﬁcient to disrupt the binding. In contrast, the E155 bond with
MAGI-3 PDZ1 is more favourable and thus its disruption has a greater
effect upon the overall binding to MAGI-3 PDZ1.
A further difference between the E6 interaction with MAGI-1 and
MAGI-3 is quite revealing. The canonical type 1 PDZ-binding motif is
x-S/T-x-V/L, but it is interesting to note that the T156 is very strongly
conserved in E6 and Serine is only found in a few HPVα subtypes that
are less commonly found in HPV-associated malignancies. Upon
mutation of T156 to Serine the degradation of both Dlg and MAGI-1 is
severely compromised, but the degradation of MAGI-3 is essentially
unaffected. Again the difference betweenMAGI-1 andMAGI-3 binding
points to a marked qualitative difference in the way these apparently
closely related PDZ domains interact with the same ligand. It also
suggests that those HPV typeswith Serine at this positionmay interact
with a different spectrum of PDZ domain-containing targets, and
indicates a marker, presence of a methyl group donor such as Iso-
leucine, by which they might be identiﬁed.
Finally, mutating the penultimate amino acid residue, Q157 to
Alanine had amarked effect upon the E6 interactionwithMAGI-1, and
a lesser effect upon its interaction with Dlg, again reﬂecting the
crystallographic analysis, which had shown both side-chain andmain-
chain binding of Q157 to MAGI-1 PDZ1, only side-chain binding to Dlg
PDZ2, and no binding to Dlg PDZ3. It is interesting to note that of the
HPV types most frequently found in malignancies, only one has a non-
polar residue in this position: it is intriguing to speculate how that HPV
type might compensate for the lack of this particular interaction, or
what differences there might be in its PDZ target spectrum. The fact
thatmodelling data indicates that Q157 does not contribute toMAGI-3
PDZ1 binding, suggests that these differences should be considered in
the context of the full PDZ-binding region of the E6 protein in question.
From the data presented here, and taken in conjunction with our
previous structural data (Zhang et al., 2007), we can say that baseline
PDZ binding is determined by the x-S/T-x-V/L motif, which is
conserved in all high-risk mucosal HPV types, but that speciﬁcity of
PDZ domain binding, and hence of substrate selection, is determined
by residues upstream of that motif as well as by the non-canonical
residues within it; this is illustrated in Fig. 7 (Zhang et al., 2007). The
degree of conservation of these peripheral and non-canonical residues
indicates the importance of these interactions in the life-cycles of
mucosal HPV types, while the rarer divergences within these regions
Fig. 7. Adapted from Zhang et al. (2007). The ﬁgure shows the crystal structures obtained with a 7-mer peptide (RRRETQV), equivalent to the C-terminal of HPV-18 E6, bound to the
MAGI-1 PDZ1, the Dlg PDZ2 and the Dlg PDZ3. Red circles indicate the residues that contribute to speci ﬁcity of binding.
377M. Thomas et al. / Virology 376 (2008) 371–378of certain HPV types suggest subtle differences in their substrate
selection, the reasons for which are as yet unclear. The ﬁnding that the
E6 proteins from three diverse HPV types appear to conform to the
predictions made here supports the importance of further analysis of
the potential binding partners of the different HPV types.
Studies such as this that begin to map the speciﬁcity determinants
of given PDZ domain/PDZ ligand interactions hold out the possibility
of our being able in future to predict whether or not a certain PDZ
domain/ligand interaction might occur in vivo, as envisaged in Fig. 8.
HPV-18 is frequently cited as being more highly transforming than
HPV-16, and some of this difference may well be accounted for by
differences in the E6 PDZ-binding sequence. The data presented hereFig. 8. The sequence alignment of a number of high-risk HPV E6 C-termini, together with
preference chart for the high-risk HPV E6 proteins, and this might be extrapolated to coverprovide a basis for predicting the potential PDZ domain-containing
targets of other HPV E6 proteins. Indeed, based on our mutational
analysis, one would predict that HPV-53 E6 would have reduced Dlg
binding capacity, and would be impaired for binding MAGI-1 and,
based on our binding assays, this would appear to be the case. These
data also provide a framework for exploring further the concept of
more aggressive types of HPV and for determining whether this is
indeed a reﬂection of their respective PDZ-binding capacities. Finally
these data should provide a blueprint from which peptido-mimetic
compounds could be designed to inhibit speciﬁc PDZ interactions,
while leaving others untouched. Such compounds could have pro-
found effects on chemotherapeutic regimes for malignancies far widerthe data presented in this paper allows us to begin to construct a possible speciﬁcity
other type I PDZ domain binding motifs.
378 M. Thomas et al. / Virology 376 (2008) 371–378than the HPV ﬁeld alone, again emphasising the usefulness of tumour




The pCDNA 3.1 plasmids expressing p53, Dlg, MAGI-1, MAGI-3 and
wild type HPV-18 E6 have been described previously (Gardiol et al.,
1999; Glaunsinger et al., 2000; Pim et al., 1994; Thomas et al., 2001).
The HPV-18 E6mutantswere constructed from the pCDNA3.1:18E6
using the Invitrogen GeneTailor system and were veriﬁed by sequen-
cing. Oligonucleotides were designed in-house and were synthesised
by MWG Biotech AG.
In vitro translation
The proteins used in this study were translated in vitro using the
TNT rabbit reticulocyte lysate system (Promega). They were radi-
olabelled with either [35S]-Cysteine or [35S]-Methionine (Amer-
sham), depending upon the sequence of the protein in question. The
levels of translated proteins were assayed by SDS-PAGE followed by
phosphorimager analysis.
In vitro degradation assays
Equal amounts of the in vitro translated target proteins (p53, Dlg,
MAGI-1 and MAGI-3) were mixed with 3× the amount of wild type or
mutant E6 protein (5× in the case of Dlg). All volumes were equalised
with water-primed lysate and incubated at 30°C. At the times
indicated in the ﬁgures, aliquots were removed and analysed by
SDS-PAGE and autoradiography. The SDS-PAGE gels were quantitated
by phosphorimager analysis and the mean % degradation at the end of
each assay was calculated, taking the sample with wild type E6 to be
100% degradation (Table 1).
GST pull-down assays
The GST-Dlg and GST-M1P1 constructs have been described
previously (Gardiol et al., 1999; Pim et al., 2002). The HPV-45, HPV-
53 and HPV-89 E6 orfs were cloned into pCDNA3.1 by pcr from the
genomic DNA. The fusion proteins were immobilised on Glutathione-
Agarose (Sigma) and incubated with in vitro translated HPV-E6
proteins radiolabelled with [35S]-Cysteine as described previously
(Gardiol et al., 1999; Pim et al., 2002).
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